1-甲基-1H-苯并咪唑-5-羧酸乙酯 | 53484-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-甲基-1H-苯并咪唑-5-羧酸乙酯
• 英文名称: ethyl 1-methyl-1H-benzo[d]imidazole-5-carboxylate
• 英文别名: ethyl 1-methyl-1H-benzimidazole-5-carboxylate；1-methyl-1H-benzoimidazole-5-carboxylic acid ethyl ester；1-Methyl-benzimidazol-carbonsaeure-(5)-ethylester；ethyl 1-methylbenzimidazole-5-carboxylate
• CAS: 53484-19-8
• 化学式: C₁₁H₁₂N₂O₂
• mdl: MFCD04501518
• 分子量: 204.228
• InChiKey: MQBXKIFEKNCNJX-UHFFFAOYSA-N

物化性质

• 熔点：
  84-85

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 1-methyl-1,3-benzodiazole-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 1-methyl-1,3-benzodiazole-5-carboxylate
CAS number: 53484-19-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H12N2O2
Molecular weight: 204.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-苯并咪唑-5-羧酸乙酯 在 lithium hydroxide 、 水 、 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 4.0h， 生成 1-甲基-1H-苯并咪唑-5-羧酸
  参考文献：
  名称：

  WO2006/128670

  摘要：

  公开号：
• 作为产物：
  描述：

  4-甲基氨基-3-硝基苯甲酸乙酯 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 1-甲基-1H-苯并咪唑-5-羧酸乙酯
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

  摘要：

  提供了一种新型杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式（1）表示：其中A代表烷基、环烷基、芳基或杂环基，基团A可能有取代基；环B代表5至8成员的单环杂环环或包含该单环杂环环的缩合环，环B可能有取代基；环C代表芳香环，环C可能有取代基；L代表包含3至5个原子的主链的连接物，所述原子选自碳原子、氮原子、氧原子和硫原子组成的群，其中主链中的至少一个原子是选自氮原子、氧原子和硫原子组成的杂原子，连接物L可能有取代基；n为0或1。

  公开号：

  US20130079306A1

文献信息

• C2-Selective Branched Alkylation of Benzimidazoles by Rhodium(I)-Catalyzed C–H Activation
  作者：Gaël Tran、Danielle Confair、Kevin D. Hesp、Vincent Mascitti、Jonathan A. Ellman

  DOI：10.1021/acs.joc.7b01723

  日期：2017.9.1

  Herein, we report a Rh(I)/bisphosphine/K3PO4 catalytic system allowing for the first time the selective branched C–H alkylation of benzimidazoles with Michael acceptors. Branched alkylation with N,N-dimethyl acrylamide was successfully applied to the alkylation of a broad range of benzimidazoles incorporating a variety of N-substituents and with both electron-rich and -poor functionality displayed

  在本文中，我们报道了Rh（I）/双膦/ K 3 PO 4催化体系，首次使苯并咪唑与Michael受体进行了选择性支链C–H烷基化。用N，N-二甲基丙烯酰胺进行的支化烷基化已成功地用于各种苯并咪唑的烷基化反应，这些苯并咪唑掺入了各种N-取代基，并且在芳烃的不同部位均显示出富电子和贫电子的功能。此外，通过用甲基丙烯酸乙酯进行烷基化来引入季碳。该方法还显示出可用于氮杂苯并咪唑的C 2-选择性支链烷基化。
• C5a Receptor Antagonists
  申请人：Schnatbaum Karsten

  公开号：US20080220003A1

  公开（公告）日：2008-09-11

  The present invention is related to a compound, preferably a C5a receptor antagonist, having the following structure, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21 and R22 are individually and independently selected from the group comprising H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, arylalkyl, substituted arylalkyl, heteroarylalkyl, substituted heteroarylalkyl, alkoxyl, substituted alkoxyl, aryloxy, substituted aryloxy, arylalkyloxy, substituted arylalkyloxy, acyloxy, substituted acyloxy, halogen, hydroxyl, nitro, cyano, acyl, substituted acyl, mercapto, alkylthio, substituted alkylthio, amino, substituted amino, alkylamino, substituted alkylamino, bisalkyl amino, substituted bisalkyl amino, cyclic amino, substituted cyclic amino, carbamoyl (—CONH 2 ), substituted carbamoyl, carboxyl, carbamate, alkoxycarbonyl, substituted alkoxycarbonyl, acylamino, substituted acylamino, sulfamoyl (—SO 2 NH 2 ), substituted sulfamoyl, haloalkyl, haloalkyloxy, —C(O)H, trialkylsilyl and azido.

  本发明涉及一种化合物，优选为C5a受体拮抗剂，其具有以下结构，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，R14，R15，R16，R17，R18，R19，R20，R21和R22分别独立选择自羟基（H）、烷基（alkyl）、取代烷基（substituted alkyl）、烯基（alkenyl）、取代烯基（substituted alkenyl）、炔基（alkynyl）、取代炔基（substituted alkynyl）、环烷基（cycloalkyl）、取代环烷基（substituted cycloalkyl）、杂环基（heterocyclyl）、取代杂环基（substituted heterocyclyl）、芳基（aryl）、取代芳基（substituted aryl）、杂芳基（heteroaryl）、取代杂芳基（substituted heteroaryl）、芳基烷基（arylalkyl）、取代芳基烷基（substituted arylalkyl）、杂芳基烷基（heteroarylalkyl）、取代杂芳基烷基（substituted heteroarylalkyl）、烷氧基（alkoxyl）、取代烷氧基（substituted alkoxyl）、芳氧基（aryloxy）、取代芳氧基（substituted aryloxy）、芳基烷氧基（arylalkyloxy）、取代芳基烷氧基（substituted arylalkyloxy）、酰氧基（acyloxy）、取代酰氧基（substituted acyloxy）、卤素（halogen）、羟基（hydroxyl）、硝基（nitro）、氰基（cyano）、酰基（acyl）、取代酰基（substituted acyl）、巯基（mercapto）、烷硫基（alkylthio）、取代烷硫基（substituted alkylthio）、氨基（amino）、取代氨基（substituted amino）、烷基氨基（alkylamino）、取代烷基氨基（substituted alkylamino）、双烷基氨基（bisalkyl amino）、取代双烷基氨基（substituted bisalkyl amino）、环状氨基（cyclic amino）、取代环状氨基（substituted cyclic amino）、氨基甲酰（—CONH2）、取代氨基甲酰、羧基（carboxyl）、氨基甲酰基（carbamate）、烷氧羰基（alkoxycarbonyl）、取代烷氧羰基（substituted alkoxycarbonyl）、酰氨基（acylamino）、取代酰氨基（substituted acylamino）、磺酰氨基（—SO2NH2）、取代磺酰氨基（substituted sulfamoyl）、卤代烷基（haloalkyl）、卤代烷氧基（haloalkyloxy）、—C（O）H、三烷基硅基（trialkylsilyl）和偶氮基（azido）。
• Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions
  申请人：Trieselmann Thomas

  公开号：US20080234278A1

  公开（公告）日：2008-09-25

  The present invention relates to new beta-agonists of general formula (I) wherein the groups R 1 to R 7 have the meanings given in the claims and specification, the tautomers, the enantiomers, the diastereomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, processes for preparing these compounds and their use as pharmaceutical compositions.

  本发明涉及通式（I）的新型β-激动剂，其中R1至R7的基团具有权利要求书和说明书中所给出的含义，它们的互变异构体、对映异构体、顺反异构体、混合物、前药及其盐，特别是与无机或有机酸或碱的生理上可接受的盐，制备这些化合物的过程以及它们作为药物组成物的用途。
• Heterocyclic compound and p27Kip1 degradation inhibitor
  申请人：Uchida Hiroshi

  公开号：US09200008B2

  公开（公告）日：2015-12-01

  A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

  提供了一种新的杂环化合物或其盐，用于选择性地抑制p27Kip1的降解。该化合物或其盐由以下式子(1)表示：其中，A表示烷基、环烷基、芳基或杂环基，基团A可以有取代基；环B表示5-至8-成员的单环杂环或含有单环杂环的紧缩环，环B可以有取代基；环C表示芳环，环C可以有取代基；L表示链连接物，包括由碳、氮、氧和硫原子中选择的3至5个原子构成的主链，其中主链中的至少一个原子是选择自氮、氧和硫原子的杂原子，链连接物L可以有取代基；n为0或1。
• Nickel-catalysed asymmetric heteroarylative cyclotelomerization of isoprene
  作者：Gong Zhang、Chao-Yang Zhao、Xiang-Ting Min、Ying Li、Xiang-Xin Zhang、Heng Liu、Ding-Wei Ji、Yan-Cheng Hu、Qing-An Chen

  DOI：10.1038/s41929-022-00825-z

  日期：——

  of an unnatural monoterpene skeleton through heteroarylative telomerization of isoprene with heterocycles. Under nickel catalysis, a series of cyclic monoterpene derivatives bearing quaternary carbon stereocentre are constructed with up to 98% yield and 97% enantiomeric excess. Preliminary mechanistic studies suggest this atom-economic reaction proceeds through an enantioselective dimerization of isoprene

  单萜类化合物是一类由香叶基二磷酸通过各种单萜合酶产生的类异戊二烯。大自然已经进化了数百万年以产生各种环状单萜。在这里，我们通过异戊二烯与杂环的杂芳基调聚，意外地创造了一种非天然的单萜骨架。在镍催化下，以高达 98% 的收率和 97% 的对映体过量构建了一系列具有季碳立体中心的环状单萜衍生物。初步的机理研究表明，这种原子经济反应通过异戊二烯的对映选择性二聚和杂环途径的顺序 C-H 烷基化进行。这项工作不仅有助于本体化学异戊二烯的有效对映选择性转化，